安捷凯在线客服
- 客服:
- 电话: 13061953619
- 微信:
AG-13958 (AG-013958), a VEGFR tyrosine kinase inhibitor, is in clinical development with ST administration for treatment of choroidal neovascularization associated with age–related macular degeneration (AMD).
AG-13958 (AG-013958), a VEGFR tyrosine kinase inhibitor, is in clinical development with ST administration for treatment of choroidal neovascularization associated with age–related macular degeneration (AMD).
[1] M.B. Kosa,et al.Investigative Ophthalmology & Visual Science. 2005;46: 5379.
动态评分
0.0